BAY 38-7271

Drugbox
IUPAC_name = (-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1-sulfonate

---

width= 220
CAS_number= 212188-60-8
ATC_prefix=
ATC_suffix=
PubChem=
DrugBank=
C=20 | H=21 | F=3 | O=5 | S=1
molecular_weight = 430.437 g/mol
bioavailability=
metabolism =
elimination_half-life=
excretion =
pregnancy_category =
legal_status = Legal
routes_of_administration=

BAY 38-7271 is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. [Mauler F, Horváth E, De Vry J, Jäger R, Schwarz T, Sandmann S, Weinz C, Heinig R, Böttcher M. BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. "CNS Drug Reviews". 2003 Winter;9(4):343-58. PMID 14647528] [Mauler F, Hinz V, Augstein KH, Fassbender M, Horváth E. Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. "Brain Research". 2003 Oct 31;989(1):99-111. PMID 14519516] It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB₁ and CB₂ receptors, with Ki values of 2.91nM at CB₁ and 4.24nM at CB₂. [Mauler F, Mittendorf J, Horváth E, De Vry J. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. "Journal of Pharmacology and Experimental Therapeutics". 2002 Jul;302(1):359-68. PMID 12065738] [De Vry J, Rüdiger Jentzsch K. Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist. "European Journal of Pharmacology". 2002 Dec 20;457(2-3):147-52. PMID 12464360]

References